Hutchinson Financial Advisors INC Takes Position in Becton, Dickinson and Company $BDX

Hutchinson Financial Advisors INC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,943 shares of the medical instruments supplier’s stock, valued at approximately $1,024,000.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC raised its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $3,458,000. Cacti Asset Management LLC raised its stake in Becton, Dickinson and Company by 0.8% in the second quarter. Cacti Asset Management LLC now owns 180,271 shares of the medical instruments supplier’s stock valued at $30,801,000 after buying an additional 1,500 shares in the last quarter. Baker Tilly Wealth Management LLC raised its stake in Becton, Dickinson and Company by 25.4% in the second quarter. Baker Tilly Wealth Management LLC now owns 6,898 shares of the medical instruments supplier’s stock valued at $1,188,000 after buying an additional 1,399 shares in the last quarter. Finally, Northside Capital Management LLC acquired a new stake in Becton, Dickinson and Company in the second quarter valued at $7,939,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $178.77 on Friday. The stock’s 50-day moving average is $188.38 and its two-hundred day moving average is $183.17. The firm has a market cap of $51.24 billion, a price-to-earnings ratio of 32.15, a PEG ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 1,895 shares of company stock worth $358,995 over the last 90 days. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of analyst reports. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Morgan Stanley raised their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Piper Sandler restated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.